DENVER, Dec. 22, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today that the Company has signed an LOI (letter of intent) with Maya. Together, the two companies plan to co-develop a novel…

Source

Previous articleEntheon Biomedical Announces Expanded Psychedelics Genetic Test Panel
Next articleOptimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department